Abstract
Cis-retinoic acid(CRA)and its metabolites have been shown to increase, in vitro, the number of Burst Forming Units Erythroid (BFU-e), the more immature erythroid precursors, in a dose-dependent manner(1). Thus, besides EPO, also retinoids might be able to correct the defective bone marrow(BM)erythroid proliferative activity in uremics (2).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Douer, D., Koeffler, H.P. J. Clin. Invest 69: 1039–1041, 1982.
Winearls, C.G., Pippard, M.J., Downing, M.R., Oliver, D.O., Reid, C. and Cotes P.M. The Lancet 22: 1175–1178, 1986.
Iscove, N.N. Cell. Tiss. Kinet. 10: 323–334, 1977.
Erslev, A.J. New England J. Med. 316: 101–103, 1987.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Kluwer Academic Publishers
About this chapter
Cite this chapter
Lamperi, S., Carozzi, S., Icardi, A., Nasini, M.G., Traverso, G.B. (1989). Treatment of Uremic Anemia with Etretinate: Comparison with Recombinant Human Erythropoietin (rHuEPO). In: Andreucci, V.E., Dal Canton, A. (eds) Current Therapy in Nephrology. Developments in Nephrology, vol 24. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0865-2_41
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0865-2_41
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8209-9
Online ISBN: 978-1-4613-0865-2
eBook Packages: Springer Book Archive